17551-52-9

Basic information

• Product Name: 4(1H)-Pyrimidinone, 6-chloro-2-methyl- (9CI)
• Synonyms: 4(1H)-Pyrimidinone, 6-chloro-2-methyl- (9CI);6-chloro-2-methylpyrimidin-4(3H)-one;6-Chloro-4-hydroxy-2-MethylpyriMidine, 97%;6-Chloro-2-MethylpyriMidin-4(1H)-one;6-Chloro-2-MethylpyriMidin-4-ol;4-Chloro-6-hydroxy-2-methylpyrimidine;6-Chloro-2-methylpyrimidin-4-ol, 4-Chloro-6-hydroxy-2-methyl-1,3-diazine;6-chloro-2-methyl-1H-pyrimidin-4-one
• CAS NO: 17551-52-9
• Molecular Formula: C₅H₅ClN₂O
• Molecular Weight: 144.559
• Product Categories: PYRIMIDINE
• Mol File: 17551-52-9.mol
• Article Data: 7

Chemical Properties

• Melting Point: 233-236°
• Boiling Point: 205.4°Cat760mmHg
• Flash Point: 78°C
• Appearance: /
• Density: 1.45g/cm³
• Vapor Pressure: 0.251mmHg at 25°C
• Refractive Index: 1.608
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 7.33±0.50(Predicted)
• CAS DataBase Reference: 4(1H)-Pyrimidinone, 6-chloro-2-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4(1H)-Pyrimidinone, 6-chloro-2-methyl- (9CI)(17551-52-9)
• EPA Substance Registry System: 4(1H)-Pyrimidinone, 6-chloro-2-methyl- (9CI)(17551-52-9)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 17551-52-9(Hazardous Substances Data)

Usage

Uses

6-Chloro-4-hydroxy-2-methylpyrimidine is an intermediate used to prepare highly potent hepatitis C Virus entry inhibitors. It is also used in the synthesis of pyrimidineacetic acids and (Pyrimidinyloxy)acetic acids as aldose reductase inhibitors.

InChI:InChI=1/C5H5ClN2O/c1-3-7-4(6)2-5(9)8-3/h2H,1H3,(H,7,8,9)

Upstream product

• 1780-26-3 2,4-dichloro-2-methylpyrimidine 
• 40497-30-1 2-methyl-1H-pyrimidine-4,6-dione 

Downstream Products

• 13162-43-1 4,6-dichloro-2-methyl-5-nitropyrimidine 
• 82779-50-8 4,6-dichloro-2-methyl-5-nitropyrimidine 
• 63586-33-4 6-chloro-2-methyl-5-nitro-pyrimidin-4-ylamine 
• 917896-29-8 3-benzyl-6-chloro-5-iodo-2-methylpyrimidin-4(3H)-one 
• 2915-15-3 4-chloro-2-methyl-6-phenyl-pyrimidine 
• 62260-39-3 6-phenyl-4-hydroxy-2-methylpyrimidine 
• 1112170-12-3 (2S,5S)-5-((5-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-2H-tetrazol-2-yl)methyl)-1,4-dioxane-2-carboxylic acid 
• 1112169-66-0 N-(4-fluoro-3-methoxybenzyl)-6-(2-(((2R,5S)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide 
• 1112169-64-8 N-(4-fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide 
• 1112178-44-5 N-(4-fluoro-3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrimidine-4-carboxamide 

Relevant articles and documents

DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis

Matrix metalloproteinase-13 (MMP-13) is a zinc-dependent protease responsible for the cleavage of type II collagen, the major structural protein of articular cartilage. Degradation of this cartilage matrix leads to the development of osteoarthritis. We previously have described highly potent and selective carboxylic acid containing MMP-13 inhibitors; however, nephrotoxicity in preclinical toxicology species precluded development. The accumulation of compound in the kidneys mediated by human organic anion transporter 3 (hOAT3) was hypothesized as a contributing factor for the finding. Herein we report our efforts to optimize the MMP-13 potency and pharmacokinetic properties of non-carboxylic acid leads resulting in the identification of compound 43a lacking the previously observed preclinical toxicology at comparable exposures.

PYRIMIDINE DERIVATIVES FOR THE TREATMENT OP GABA B MEDIATED NERVOUS SYSTEM DISORDERS

The invention relates to novel heterocyclic compounds of the formula (I) in free base form or in acid addition salt form, in which R1, R2, R3, R4 and A are as defined in the specification, to their preparation, to their use as medicaments for the treatment of certain nervous system disorders and to medicaments comprising them.